Histamine modulates hippocampal inflammation and neurogenesis in adult mice

Cláudia Saraiva¹, Sandra Barata-Antunes¹, Tiago Santos¹,², Elisabete Ferreiro³,
Ana Clara Cristóvão¹, Catarina Serra-Almeida⁴, Raquel Ferreira¹ & Liliana Bernardino¹

Evidence points to a dual role of histamine in microglia-mediated neuroinflammation, a key pathological feature of several neurodegenerative pathologies. Moreover, histamine has been suggested as a modulator of adult neurogenesis. Herein, we evaluated the effect of histamine in hippocampal neuroinflammation and neurogenesis under physiological and inflammatory contexts. For that purpose, mice were intraperitoneally challenged with lipopolysaccharide (LPS) followed by an intrahippocampal injection of histamine. We showed that histamine per se triggered glial reactivity and induced mild long-term impairments in neurogenesis, reducing immature neurons dendritic volume and complexity. Nevertheless, in mice exposed to LPS (2 mg/Kg), histamine was able to counteract LPS-induced glial activation and release of pro-inflammatory molecules as well as neurogenesis impairment. Moreover, histamine prevented LPS-induced loss of immature neurons complexity as well as LPS-induced loss of both CREB and PSD-95 proteins (essential for proper neuronal activity). Altogether, our results highlight histamine as a potential therapeutic agent to treat neurological conditions associated with hippocampal neuroinflammation and neurodegeneration.

Histamine is an endogenous biogenic amine classically associated with peripheral allergic and inflammatory reactions but it can regulate both brain inflammation¹ and neurogenesis². Histamine action is mediated by the activation of four different G protein-coupled receptors: histamine H1 receptor (H1R), H2R, H3R and H4R, which are differentially expressed in distinct brain cell phenotypes³. Several studies demonstrated the ability of histamine to modulate the brain inflammatory response by: (i) increasing microglial cell mobility through a signaling pathway involving α5β2 integrin, p-38 and Akt⁵; (ii) prompting the release of pro-inflammatory mediators, namely tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), through H1R and H4R⁶; (iii) promoting microglial phagocytic activity by the activation of H1R and (iv) inducing reactive oxygen species (ROS) production via Nox1 signaling pathway⁷. Thus, under a physiological context, histamine seems to induce a pro-inflammatory phenotype causing neuronal damage or even neuronal degeneration⁸. On the other hand, histamine has been shown to counteract LPS-induced inflammation. In fact, histamine decreased microglial migration, phagocytosis and ROS production induced by LPS as well as the release of interleukin-1β (IL-1ß)⁹ and prostaglandin E2¹⁰. As such, histamine seems to have a dual role in the central nervous system (CNS) depending on the microenvironment, the activation state of cells and which histamine receptor is activated. Interestingly, it was recently demonstrated that initial peripheral inflammatory stimuli, such as LPS, generates immune memory in brain macrophages (microglia) resulting in a differential immune response to subsequent stimuli¹⁰. This immune memory contributes to the modulation of several neurological pathologies and might also explain the dual role of histamine.

Another important process regulated by histamine is adult neurogenesis, which occurs constitutively throughout life, mainly in the subventricular zone (SVZ) and in the hippocampal subgranular zone (SGZ). In vitro studies showed that H1R, H2R and H3R are expressed in neural stem cell (NSC) niches and that histamine induces NSC proliferation and neuronal differentiation through H2R and H1R signaling pathways, respectively¹¹,¹². In fact, histamine activation of H1R results in SVZ NSC differentiation via Mash1, DLX2 and Ngn1 into mature neurons, enabling the integration and differentiation of SVZ progenitors when grafted onto hippocampal slices.
or in the mouse hippocampus and striatum in vivo. Moreover, intraventricular infusion of histamine into the lateral ventricles induces a significant increase in the number of SVZ neuroblasts capable of migrating towards the olfactory bulb where they differentiate into mature neurons. Interestingly, H1R knockout mice present a reduced number of proliferative cells in the hippocampal dentate gyrus (DG) together with pronounced deficits in spatial learning and memory. Additionally, the hippocampal inactivation of H3R, using the specific antagonist S38093, promoted neurogenesis in young and aged mice. Remarkably, the performance of aged mice in a context discrimination task was also improved. These studies indicate that histamine might also modulate SGZ neurogenesis.

Altogether, unraveling the multiple actions of histamine might lead to the development of anti-inflammatory and regenerative therapies for both acute brain pathologies (e.g. ischemic stroke) and neurodegenerative disorders (e.g. Parkinson’s disease (PD), Alzheimer’s disease (AD)). Nevertheless, there is a lack of information regarding the effects of increased histamine levels in the hippocampus, a brain region that plays a key role in behavior and cognitive performance and that is compromised under neuroinflammatory conditions. In this sense, we evaluated the effects of histamine per se or under an inflammatory context mimicked by LPS in both hippocampal neuroinflammation and neurogenesis in adult mice. Herein, we report a pro-inflammatory role for histamine per se and its anti-inflammatory action after LPS stimulus. Moreover, we show that histamine can revert the loss of volume and arbor complexity of newborn neurons caused by LPS. Overall, we validate histamine as a potential therapeutic molecule in the fight against neuroinflammatory conditions.

Materials and Methods

Mice. All animal experiences were conducted in agreement with protocols approved by the national ethical requirements for animal research and the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (European Union Directive number 192 2010/63/EU). The in vivo experiments were carried out by investigators with the training required by present legislation (Functions B and C defined in article 23 of EU Directive 2010/63), and were authorized by the Animal-Welfare Body of the Health Research Centre at the University of Beira Interior (CICS-UBI) in compliance with the national legislation (EU Directive 2010/63, Chapter I, article 3). Two to five months-old C57BL/6 male mice were used. Mice were housed in the same room and in similar cages under controlled conditions: 12h light/dark cycle at temperature of 22°C and ad libitum access to food and water. All efforts were made to minimize the number of animals used in the study.

Intraperitoneal and stereotaxic injections. Mice were initially subjected to an intraperitoneal injection (i.p.) of LPS (from Escherichia coli 055:B5, Sigma-Aldrich Co. LLC, St. Louis, MO, U.S.A.), at 1 mg/Kg or 2 mg/Kg, diluted in 0.1 M sterile phosphate buffered-saline (PBS) at pH 7.4. Mice intraperitoneally injected with 0.1 M of sterile PBS were considered the control condition. Two days after LPS administration, mice were anesthetized with an i.p. injection of ketamine (90 mg/Kg of mouse weight; Imalgene 1000, Merial, Lyon, France) and xylazine (10 mg/Kg of mouse weight; Rompun 2%, Bayer, Leverkusen, Germany) and placed in a digital stereotaxic frame (S1900 Stoeling, Dublin, Ireland). A unilateral intracerebral injection of 2 μL of sterile histamine dihydrochloride (100 μM His in PBS, Sigma-Aldrich Co. LLC; ipsilateral) was performed in the DG of the hippocampus (anteroposterior: -1.9 mm, mediolateral: -1.2 mm, and dorsoventral: -1.8 mm from bregma) using a Hamilton syringe (Hamilton, Reno, NV, USA) at a speed of 0.2 μL/min. After intracerebral injection, the incision was sutured, and mice were kept warm (37°C) until they recovered from anesthesia. Six experimental conditions were analyzed: i) contralateral hemisphere of mice subjected to i.p. injections of PBS and to intracerebral injection of 100 μM His - PBS contralateral group or “PBS”; ii) ipsilateral hemisphere of mice subjected to i.p. injections of PBS and to intracerebral injection of 100 μM His - “His”; iii) contralateral hemisphere of mice subjected to i.p. injections of 1 mg/Kg of LPS and to intracerebral injection of 100 μM His - “1 mg/Kg LPS + His”; iv) ipsilateral hemisphere of mice subjected to i.p. injections of 1 mg/Kg of LPS and to intracerebral injection of 100 μM His - “1 mg/Kg LPS + His”; v) contralateral hemisphere of mice subjected to i.p. injections of 2 mg/Kg of LPS and to intracerebral injection of 100 μM His - “2 mg/Kg LPS + His”; and vi) ipsilateral hemisphere of mice subjected to i.p. injections of 2 mg/Kg of LPS and intracerebral injection of 100 μM His - “2 mg/Kg LPS + His”. This categorization is only possible because no significant differences among the contralateral side of mice injected i.p. with saline and histamine in the hippocampus (ipsilateral side) were found when compared with both the ipsilateral and the contralateral sides of sham mice (i.p. injection of saline followed by hippocampal injection of histamine, data not shown).

To unveil the effects of histamine in hippocampal neuroinflammation, animals were euthanized 2 days after histamine stereotaxic injection and brains were removed for immunoblot analysis. To label dividing cells and evaluate the effects of histamine in neuroblast proliferation in the DG, 5-bromo-2′-deoxyuridine (BrdU; 100 mg/Kg of animal weight, Sigma-Aldrich Co. LLC) dissolved in sterile saline solution (0.9% NaCl) was injected i.p. the following 2 days (every 12h) after the stereotaxic procedure. Mice were maintained for 3 days after histamine treatment before being euthanized for further immunohistochemistry analysis. Lastly, to uncover the effects of histamine in the survival of newborn neurons and their dendritic complexity in the DG, BrdU i.p. injections (50 mg/Kg of animal weight in 0.9% NaCl) were performed every 12h during the first 3 days after the histamine stereotaxic injection. Mice were euthanized six weeks after histamine treatment for further immunohistochemical analysis. Animal weight was daily monitored throughout all the experiments and no significant changes were observed (data not shown).

Tissue collection. At day 2 after histamine stereotaxic injection, mice were decapitated and the hippocampi were dissected and immediately frozen in liquid nitrogen and stored at −80°C until protein extraction processing and western blotting analysis. At day 3 and week 6 after intracerebral injection, mice were deeply anesthetized with a mixture of ketamine and xylazine (90 mg/Kg and 10 mg/Kg of mouse weight, respectively) and perfused intracardially with saline.
solution, followed by 4% paraformaldehyde (PFA, Sigma-Aldrich Co. LLC). Brains were removed and post-fixed in 4% PFA for 24 h at 4 °C followed by immersion in a 30% sucrose solution (Fisher Scientific, Pittsburgh, PA, USA) until sunk. Then, brains were cryopreserved and 40 μm coronal sections of the hippocampus were collected in series of 12 sequential slices (spaced 460 μm each) using a cryostat-microtome (Leica CM3050S, Leica Microsystems, Nussloch, Germany). Slices were stored in cryopreservation solution (30% glycerol, 30% ethylene glycol and 10% phosphate buffer (0.2 M)) at −20 °C until immunohistochemistry staining.

**Western blotting.** Hippocampal tissues were mechanically dissociated and lysed on ice in RIPA buffer (0.15 M NaCl, 0.05 M Tris, 5 mM ethylene glycol tetraacetic acid, 1% Triton X-100, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulphate, 10 mM dithiothreitol, 100 mM Tris-HCl, 0.01% sodium azide) containing a cocktail of proteinase inhibitors (Roche, Basel, Switzerland). The protein soluble fraction was obtained by centrifugation at 17,700 g for 20 min at 4 °C, after vortex homogenization. The total protein concentration from the lysates was determined using the bicinchoninic acid assay (BCA; Thermo Scientific, MA, USA). Protein samples were denatured in SDS-PAGE buffer (350 mM Tris, 10% (w/v) SDS, 30% (v/v) glycerol, 0.6 M DTT, 0.06% (w/v) bromophenol blue) for 5 min at 95 °C. Proteins (40 μg or 80 μg of total protein) were resolved in 8% or 12% SDS polyacrylamide gels at 90–100 V and then transferred to polyvinylidene difluoride (PVDF) membranes (GE Healthcare, Buckinghamshire, UK) in the following conditions (Trans-blot Turbo System, BioRad Laboratories, CA, USA): 1.0 A, 25 V, 15–30 min, using Towbin transfer buffer (25 mM Tris, 192 mM glycine pH 8.3, 20% methanol) at room temperature (RT). To block non-specific binding, the membranes were incubated with a tris-buffer saline (TBS) containing 0.1% Tween-20 (Thermo Fisher Scientific, Waltham, MA, USA), and 5% low-fat milk or 5% BSA (Amresco LLC, Solon, USA) or 0.1% gelatin (Fluka, St Louis, MO, USA), depending on the antibody used, for 20 min at RT. Membranes were then incubated overnight at 4 °C with appropriate primary antibodies diluted in blocking solution: mouse anti-ionized calcium binding adaptor molecule 1 (Iba-1; 1:200, Santa Cruz Biotechnology Dallas, TX, U.S.A.); mouse anti-glial fibrillary acidic protein (GFAP; 1:5000, Santa Cruz Biotechnology); rabbit anti-interleukin-1 beta (IL-1β; 1:200, HMGBiotech, Milano, Italy); mouse anti-high mobility group box 1 protein (HMGB1; 1:500, Cell Signaling, Beverly, MA, USA); rabbit anti-cAMP response element binding protein (CREB; 1:1000, Cell Signaling); mouse monoclonal anti-actin (1:1000, BD Biosciences; Franklin Lakes, NJ, U.S.A); mouse monoclonal anti-β-galactosidase 1-phosphate dehydrogenase protein (GAPDH; 1:5000, Merck Millipore) and mouse anti-tubulin (1:5000, Sigma-Aldrich Co. LLC); followed by the respective secondary antibody (1 h), both at RT. Protein immunoreactive bands were visualized in a Chemidoc™MP imaging system (BioRad Laboratories) after incubation with NZY superior ECL reagent (NZYTech, Lisbon, Portugal). Densitometric analysis was performed using the software ImageLab (BioRad Laboratories). Full-length blots are included in the supplementary data.

**Immunohistochemistry.** The immunostaining assays were performed using a protocol adapted from18. First, brain sections were incubated with 2 M HCl for 25 min at 37 °C to induce DNA denaturation. After washing with PBS, tissue sections were further incubated in a blocking solution containing 2% of horse serum (Life Technologies, Carlsbad, CA, USA) and 0.3% Triton X-100 (Fisher Scientific) diluted in 0.1 M PBS for 2 h at RT. After the blocking procedure, tissue sections were incubated for 72 h at 4 °C in the following primary antibodies (diluted in the blocking solution): rat monoclonal anti-BrdU (1:500, AbD Serotec, Raleigh, NC, USA), goat polyclonal anti-doublecortin (DCX; 1:500, Santa Cruz Biotechnology), or mouse monoclonal anti–NeuN (1:500, Merck Millipore). Then, sections were rinsed in PBS and incubated with Hoechst (1:1000; Sigma-Aldrich Co. LLC) and the respective secondary antibodies: Alexa Fluor-488 donkey anti-rat, Alexa Fluor-546 donkey anti-goat or anti-mouse (all 1:500; all Life Technologies), diluted in a solution containing 0.3% Triton X-100 in 0.1 M PBS, for 2 h at RT. Finally, sections were rinsed in PBS and mounted in Fluoroshield Mounting Medium (Abcam Plc., Cambridge, UK) for further analysis.

**Cell number and volume quantification.** Neuroblast proliferation analysis. To assess neuroblast proliferation, fluorescence immunostaining z-stack projections of the DG were acquired in serial sections at 480 μm rostrocaudal intervals along the entire hippocampus (bregma −3.88 mm to bregma −0.94 mm) using an AxioObserver LSM 710 confocal microscope (Carl Zeiss, Jena, Germany) under a 63x oil immersion objective. BrdU-positive (BrdU+) and BrdU/DCX-double positive (BrdU+/DCX+) cells were counted in these serial sections using ImageJ software (NIH Image, Bethesda, MD, USA) in the SGZ of mice 3 days after histamine administration. Total number of BrdU+ and BrdU+/DCX+ cells was estimated using the Abercrombie formula: T = (N × V)/(t + D), in which T is the total number of cells, N is cell density, V is the total volume of the considered area, t is slice thickness (40 μm) and D is average cellular diameter (cell diameters from 6 random cells per experimental condition)19.

**Survival of newborn neurons analysis.** To assess survival of newborn neurons, BrdU+/NeuN+ cells were counted in serial sections at 240 μm rostrocaudal intervals along the entire hippocampus, using an AxioObserver LSM 710 confocal microscope under a 63x oil immersion objective. Total number of BrdU+/NeuN+ cells from the hippocampus of 6-week-old mice, after histamine treatment, was estimated by applying the Abercrombie formula, as described previously.
Area and volume quantification. To estimate area and volume, images of the DG were taken in serial sections at 240 or 480 μm rostrocaudal intervals along the entire hippocampus. The images were obtained using an AxiosObserver LSM 710 confocal microscope under a 10x objective. The areas were estimated delineating a line around DCX using the Fiji software (NIH, Bethesda, MD, USA). The volume was estimated through the equation: \( V (\mu m^3) = \sum_{i=1}^{n} A_i \times d^2 \), in which A is the area of each section and d corresponds to the interval between slices (240 or 480 μm).

Dendritic morphology analysis. To assess neuroblast volume and dendritic complexity 3D reconstructions from confocal stack images of DCX⁺ cells obtained using an AxiosObserver LSM 710 confocal under a 40x oil immersion objective were made. Mice euthanized 6 weeks after histamine treatment were used for this analysis. 3D reconstructions were made using the simple neurite tracer plugin in Fiji Software. For this purpose, we analyzed 20 DCX⁺ cells in "1 mg/Kg LPS" and "1 mg/Kg LPS + His" conditions and 30 DCX⁺ cells for "PBS", "His", "2 mg/Kg LPS" and "2 mg/Kg LPS + His" conditions from 3 sequential coronal sections separated by 240 μm of the suprapyramidal region of the SGZ (bregma −2.3 mm to bregma −1.8 mm) from 2 or 3 different mice, respectively. Dendritic morphology was analyzed in the Fiji software using the 3D Sholl analysis plugin that quantifies the number of intersections between Sholl circles (with a 15 μm increment) and dendrites. After the 3D reconstruction of the entire neuronal dendritic tree, the individual neuronal volume was also quantified using DCX staining and the fill out function in the Simple neurite tracer plugin.

Data analysis. Data are shown as the mean ± standard error of the mean (SEM), expressed as either percentages of values obtained in PBS condition or absolute values. Statistical analysis was performed using one-way ANOVA, followed by the post-hoc test Dunnett Multiple Comparison Test to measure differences between the PBS condition and the other experimental conditions. To assess differences between the pairs LPS condition and LPS + His condition for either concentration of LPS (1 or 2 mg/Kg) the one-way ANOVA followed by the Sidak Multiple Comparison Test was used. For Sholl analysis a two-way ANOVA, followed by Tukey test was used. In this way, for every distance from the soma assessed, the mean of the intersection numbers obtained for each condition were compared with all the other conditions. F values are described for each ANOVA analysis and values of P < 0.05 were considered significant. All statistical analysis was done using GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA).

Results
Histamine modulates inflammation in mouse hippocampus. First, to identify the role of histamine in hippocampal inflammation we assessed by western blotting the levels of GEAP and Iba-1 proteins to correlate with the levels of activated astrocytes and microglia, respectively, as well as the expression of the inflammatory mediators IL-1β and HMGB1 in LPS-challenged mice treated or not with histamine (Fig. 1). We observed that histamine per se significantly increased the reactivity of astrocytes (GEAP: PBS 100.0 ± 15.9, His 161.7 ± 8.8, n = 5–6, F = 4.016, P = 0.0126; Fig. 1B) and tended to increase the reactivity of microglia (Iba-1: PBS 100.0 ± 15.9, His 186.7 ± 20.3, n = 7, F = 4.226, P = 0.0716; Fig. 1C). As expected, both LPS dosages induced glial reactivity with 2 mg/Kg promoting a higher inflammatory response. The glial reactivity induced by 2 mg/Kg of LPS was reversed by the local administration of 100 μM of histamine in LPS-challenged mice treated or not with histamine (PBS condition and the other experimental conditions. To assess differences between the pairs LPS condition and LPS + His condition for either concentration of LPS (1 or 2 mg/Kg) the one-way ANOVA followed by the Sidak Multiple Comparison Test was used. For Sholl analysis a two-way ANOVA, followed by Tukey test was used. In this way, for every distance from the soma assessed, the mean of the intersection numbers obtained for each condition were compared with all the other conditions. F values are described for each ANOVA analysis and values of P < 0.05 were considered significant. All statistical analysis was done using GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA).

Histamine modulates mouse hippocampal neurogenesis. Neuroinflammation has been implicated in the impairment of adult neurogenesis16. To unveil the effects of histamine in SGZ neurogenesis, we assessed the total number of proliferative cells (BrdU⁺/DCX⁺ cells) along the entire SGZ, in mice exposed to saline or LPS (1 or 2 mg/Kg) and later on treated with 100 μM of histamine (Fig. 2A). We found that histamine positively influenced the levels of total BrdU⁺ cells without altering the levels of BrdU⁺/DCX⁺ cells when compared with control. Nevertheless, in mice exposed to LPS, histamine significantly increased the total amount of proliferative cells (PBS, 100.0 ± 10.1; 1 mg/Kg, LPS 98.8 ± 4.7; 1 mg/Kg of LPS + His, 197.6 ± 28.2, 2 mg/Kg, LPS 96.7 ± 9.7; 2 mg/Kg of LPS + His, 154.1 ± 23.8 n = 3–4; F = 3.579, *P = 0.0326, **P = 0.081, †P = 0.0251; Fig. 2B), but did not change the levels of BrdU⁺/DCX⁺ cells (Fig. 2C). Interestingly, LPS did not show an effect in DG overall proliferation nor in the number of proliferative neuroblasts (Fig. 2B,C).

We have further evaluated the effects of histamine per se and under LPS challenge in the long-term survival of newborn neurons (BrdU⁺/NeuN⁺ cells) in mice exposed to saline or LPS (1 or 2 mg/Kg) and treated with 100 μM of histamine 2 days later, which were euthanized 6 weeks after histamine administration (Fig. 3A). Histamine per se tended to increase the number of BrdU⁺/NeuN⁺ cells (Fig. 3B,C), while no significant effect was induced by any of LPS concentrations tested. Notably, histamine in the presence of a pre-conditioning LPS stimulus significantly increased the number of BrdU⁺/NeuN⁺ cells (PBS, 100.0 ± 13.6; 1 mg/Kg LPS, 93.5 ± 21.2; 1 mg/Kg LPS + His, 178.3 ± 58.3; 2 mg/Kg LPS, 94.6 ± 10.4; 2 mg/Kg LPS + His, 208.7 ± 42.8, n = 2–4; F = 3.568, *P = 0.0477, †P = 0.0130 Fig. 3B).

Histamine ameliorates the loss of neuronal complexity of hippocampal neuroblasts caused by LPS. To further understand the long-term effects of histamine per se or under inflammatory conditions in the population of newborn neurons, we assessed the size and the dendritic complexity of immature neurons.
6 weeks after histamine treatment (Fig. 3A), DCX+ cells from these animals were 3D reconstructed and the volumetric integration of DCX+ cells (Fig. 4) and DCX dendritic complexity (Fig. 5) evaluated. We observed that histamine per se and both concentrations of LPS induced a significant volumetric reduction of the dendritic arborization of DCX+ cells. On the other hand, in the presence of the inflammatory preconditioning stimulus (LPS), histamine was able to revert the LPS-induced loss of neuronal volume (PBS, 418.6 ± 32.7; His, 316.4 ± 24.6; 1 mg/Kg LPS, 238.6 ± 19.7; 1 mg/Kg LPS + His, 331.1 ± 33.4; 2 mg/Kg LPS, 248.7 ± 18.8; 2 mg/Kg LPS + His, 334.3 ± 24.8, n = 20–30 cells of at least 2 different animals, F = 6.20, *P < 0.05, **P < 0.01 and ***P < 0.001 when compared with PBS condition). Comparison of the following pairs: 1 mg/kg LPS vs 1 mg/kg LPS + His and 2 mg/kg LPS vs 2 mg/kg LPS + His was done by one-way ANOVA followed by the Sidak Multiple Comparison Test (#P < 0.05, ##P < 0.01).

Histamine reverts synaptic plasticity loss caused by LPS in the mouse hippocampus. Finally, to understand if the loss of dendritic complexity observed in 2 mg/Kg LPS-challenged mice and if the protective role

Figure 1. Histamine inhibits LPS-induced glial reactivity in the mouse hippocampus. (A) Adult mice were subjected to intraperitoneal injections (i.p.) of either PBS or LPS (day 0), followed by intracerebral administration of histamine in the hippocampus (day 2). Protein extraction from the hippocampus was performed at day 4. Bar graphs depict the percentage relative to PBS condition of GFAP (B), Iba-1 (C), IL-1β (D) and HMGB1 (E) protein expression. White bars represent mice contralateral hemisphere and black bars the ipsilateral hemisphere. On the right of each bar graph, representative image of the respective protein analyzed and the housekeeping (HK) protein used (GAPDH, 37 KDa; tubulin, 50 KDa; and actin, 42 KDa) are shown. Data are expressed as percentage of PBS ± SEM. Statistical analysis was performed using one-way ANOVA, followed by Dunnett Multiple Comparison Test (n = 4–7; *P < 0.05, **P < 0.01 and ***P < 0.001 when compared with PBS condition). Comparison of the following pairs: 1 mg/kg LPS vs 1 mg/kg LPS + His and 2 mg/kg LPS vs 2 mg/kg LPS + His was done by one-way ANOVA followed by the Sidak Multiple Comparison Test (#P < 0.05, ##P < 0.01).
of histamine was preceded by any alterations in terms of synaptic activity or neuronal function, the total levels of PSD-95 and CREB were evaluated by western blotting. The hippocampal tissue was obtained from mice exposed to the experimental setup described in Fig. 1A. CREB is a nuclear transcription factor that modulates neuronal plasticity and cognition22. CREB downregulation and signaling dysfunction have been implicated in neuroinflammatory conditions23. As such, evaluation of both CREB and the postsynaptic protein PSD-95 can be used as indirect indicators of neuronal functionality. Herein, we observed a significant reduction in the levels of both CREB and PSD-95 in the 2 mg/Kg of LPS condition. Histamine per se did not alter CREB and PSD-95 levels (Fig. 6A,B).

On the other hand, when mice were pre-conditioned with LPS, histamine prevented the reduction of CREB and PSD-95 protein levels (CREB: PBS, 100.0 ± 3.9; 2 mg/Kg LPS, 65.3 ± 7.2; 2 mg/Kg LPS + His, 83.1 ± 2.7; n = 6–7, F = 11.15, ****P < 0.0001; PSD-95: PBS, 100 ± 12.7; 2 mg/Kg LPS, 55.8 ± 9.9; 2 mg/Kg LPS + His, 110.1 ± 12.9; n = 6, F = 4.59, *P = 0.0370, ##P = 0.0036; Fig. 6A,B).

Discussion
Evidence has been pointing to neuroinflammation as a trigger in neurodegenerative disorders and cognitive decline24–26. In the brain, histamine can act either as neurotransmitter or as modulator of the innate immune system. Herein, we investigated the effects of histamine in mice hippocampal inflammation and neurogenesis, both in physiological conditions and under peripheral inflammation. For that purpose, mice were subjected to i.p. administration of LPS at two different dosages followed by the intrahippocampal administration of histamine.

Concomitant with other studies5,7,27, we also observed that in physiological conditions histamine acts as a pro-inflammatory mediator, increasing both astrocytic and microglia reactivity. Nevertheless, no alterations in the levels of IL-1β or HMGB-1, two pro-inflammatory molecules, were observed. The maintenance of IL-1β levels after histamine stimulus was also previously demonstrated by us on a microglial cell line (N9) and in hippocampal organotypic slice cultures5. On the other hand, the peripheral administration of LPS increased both astrocytic and microglia reactivity as well as production of pro-inflammatory molecules. Interestingly, histamine was able to inhibit glial reactivity and the release of pro-inflammatory molecules in mice previously challenged with 2 mg/...
Kg of LPS. Noteworthy, we have previously showed that co-administration of histamine with LPS does not induce cell death in a microglial cell line. Moreover, no alterations in cleaved caspase-3 protein levels (an indicator of apoptosis) were observed in this study (data not shown), indicating that glial reactivity reduction does not derive from cell death.

**Figure 3.** Histamine enhances survival of newborn neurons in the hippocampal DG in LPS-challenged mice. Adult mice were subjected to intraperitoneal injections (i.p.) of either PBS or LPS (day 0), followed by intracerebral administration of histamine in the hippocampus (day 2). Then, mice received intraperitoneal injections of 50 mg/Kg of BrdU every 12 h (day 3, 4 and 5). Thereafter, mice were perfused for histological analysis at the end of week 6. (B) Graph represents the percentage relative to PBS of total number of BrdU+/NeuN+ neurons in the hippocampal DG. (C) Representative confocal images of cell nuclei (Hoechst, blue), BrdU (green; white arrows) and NeuN (red; white arrows) were obtained in hippocampal DG mouse slices. Scale bar is 10 μm. Data are expressed as percentage of PBS ± SEM. PBS condition was set to 100%. Statistical analysis was performed using one-way ANOVA followed by Dunnett Multiple Comparison Test (*P < 0.05 compared to PBS condition). One-way ANOVA followed by the Sidak Multiple Comparison Test was used to assess differences between 2 mg/kg LPS and 2 mg/kg LPS + His, #P < 0.05.

**Figure 4.** Histamine counteracts volume loss of hippocampal DG immature neurons caused by LPS. Adult mice were subjected to intraperitoneal injections of either PBS or LPS (day 0), followed by intracerebral administration of histamine in the hippocampus (day 2). Thereafter, mice were perfused for histological analysis at the end of week 6. (A) Three dimensional reconstructions of representative DCX+ cells of the hippocampal DG. Scale bar 50 μm. (B) Graph represents the volume of the dendritic tree from the reconstructed DCX+ immature neurons. Statistical analysis was performed using one-way ANOVA, followed by Dunnett Multiple Comparison Test (n = 20–30 cells from at least 2 different animals; *P < 0.05 and ****P < 0.0001 when compared to control condition). Comparison of the following pairs: 1 mg/kg LPS vs 1 mg/kg LPS + His and 2 mg/kg LPS vs 2 mg/kg LPS + His was done by one-way ANOVA followed by the Sidak Multiple Comparison Test, #P < 0.05.
from microglial cell death. Our data are in agreement with previous studies showing that histamine can have a dual role in the modulation of inflammation depending on the microenvironment and the activation state of glial cells5,9,28.

LPS administration is one of the most used and well-characterized approaches to induce inflammation, both in the CNS and periphery. LPS signals mainly through toll-like receptor 4 (TLR-4), which is located on microglia, astrocytes and endothelial cells in the CNS29. Some studies have reported that LPS induces an upregulation of the expression of histamine receptors. A higher H1R expression was reported in human coronary artery endothelial cells (HCAEC) after LPS exposure in a dose-dependent manner30. In a rat microglial cell line, stimulation with LPS (100 ng/mL) also resulted in a higher expression of the H4R (peak 24 h). Similarly, significant increase of H4R expression levels (from day 1 to at least day 7) were observed in the cortex of rats subjected to intracerebroventricular injections of LPS (1 µg/µl)31. Interestingly, a recent study showed that a single peripheral administration of different dosages of LPS (100 µg/Kg or 1 mg/Kg) resulted in a differential inflammatory response in the brain32. In fact, the authors reported that low dosages of LPS (100 µg/Kg) promote microglial activation only in the circumventricular organs and neighboring regions, while the higher concentration of LPS (1 mg/Kg) was able to activate microglia in many other regions (e.g. DG, corpus callosum, cerebellum, etc). Nevertheless, it is important to notice that even microglia reactivity in the DG after administration of 1 mg/Kg of LPS was still low comparing with other brain regions32, indicating that higher concentrations of LPS might be necessary to lead to a more robust inflammatory response in this region. Moreover, there are recent evidence of an innate brain immune memory caused by peripheral stimuli. Wendeln and colleagues recently demonstrated that inflammatory peripheral stimuli, such as LPS, induce an immune memory in the brain. This effect was mainly mediated by microglia, leading to either training (enhancing immune response) or tolerance (suppressing immune response). Interestingly, the immune memory, which occurs through epigenetic reprogramming, was also able to affect the severity of subsequent neurological disorders for at least 6 months in mice10. Inflammatory memory in epithelial stem cells was also similarly described, leading to wound healing promotion33.

Herein, we demonstrate the histamine potential to counteract LPS-induce damage in the hippocampus of mice that is more pronounced when a higher concentration of LPS (2 mg/Kg) is given. Considering the previously mentioned studies and our results, the superior anti-inflammatory and pro-neurogenic response induced by histamine when 2 mg/Kg LPS was given might be due to a weaker inflammatory response due to low availability of LPS in the DG when 1 mg/Kg is used and/or the acquisition of immune tolerance when 2 mg/Kg of LPS is administered. Nevertheless, the anti-inflammatory role induced by histamine reported by us is in agreement with other reports showing that histamine is able to suppress LPS-induced inflammation in human monocytes34,35, human monocyte-derived dendritic cells36, in microglia1,9, in the liver, and in the substantia nigra1,37,38. In these situations, histamine reduced the expression of pro-inflammatory cytokines (e.g. TNF-α, INF-γ, IL-18), led to cytoskeleton rearrangements and inhibited microglial activation, namely in terms of the phagocytic activity and

**Figure 5.** Histamine enhances dendritic complexity of hippocampal DG neuroblasts in LPS-challenged mice. Adult mice were subjected to intraperitoneal injections of either saline or LPS (day 0), followed by intracerebral administration of histamine in the hippocampus (day 2). Thereafter, mice were perfused for histological analysis at the end of week 6. (A–C) 3D Sholl analysis of DCX+ cells from the hippocampal DG. Graphs represent the number of dendritic intersections with Sholl circles in each radius comparing: PBS condition and histamine condition (A); PBS, 1 mg/Kg LPS and 1 mg/Kg LPS + Histamine conditions (B); and control, 2 mg/Kg LPS and 2 mg/Kg LPS + Histamine conditions (C). Statistical analysis was performed using two-way ANOVA, followed by the Tukey’s Comparison Test (n = 20–30 cells from at least 2 different animals; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 when compared to PBS condition; #P < 0.05 and ##P < 0.01 when compared to the respective LPS-treated condition).
ROS production\(^1,^9,^{36-38}\). Since LPS induces an upregulation of histamine receptors, a higher concentration of LPS (2 mg/kg) may be needed to boost its anti-inflammatory and protective effects in the DG.

Herein, we did not evaluate the mechanisms underlying the anti-inflammatory effects driven by histamine under LPS treatment. We have showed previously that the protective effect of histamine on a microglia cell line (N9) and hippocampal organotypic slices under LPS challenge was mediated by H4R\(^5\). Later we also demonstrated that histamine decreases microglial phagocytosis activity and ROS production induced by LPS in both the N9 cell line and in mouse primary microglia cultures. This effect of histamine was shown to be at least partially modulated by H1R and H4R. In contrast, the dopaminergic cell death induced by LPS in the mouse substantia nigra was rescued by histamine exposure through H1R\(^7\). Iida and collaborators showed that in mouse primary microglia cultures the H3R (presynaptic receptor that inhibits synthesis and release of histamine and other neurotransmitters) agonist imetit inhibited microglial chemotaxis, phagocytosis and LPS-induced production of cytokines\(^9\). The same authors have later on shown the opposite results in ex vivo mouse hippocampal organotypic slices and in in vivo conditions, since H3R inverse agonist ([JN]10181457) led to a reduction in LPS-induced microglial phagocytosis and cytokine expression as well as to the attenuation of depression-like behaviors caused by LPS\(^39\). Interestingly, Guillox and collaborators recently showed that chronic administration of the H3R antagonist/reverse agonist S 38093 in mice promotes hippocampal neurogenesis in young adult mice, aged mice and in a transgenic model of AD. Moreover, this treatment was able to improve the performance of aged mice in a context discrimination test\(^15\). These studies demonstrate that the histamine mode of action might vary depending on the experimental conditions (e.g. in vitro, in vivo studies; brain regions; amount of histamine administered; type of pathology/stimuli used). Therefore, further studies are needed to disclose the type of histamine receptors and signaling pathways involved in the histamine protective role in neurological disorders with an inflammatory component (e.g. ischemic stroke, AD, PD, multiple sclerosis)\(^1,^40\).

Inflammation has a negative effect on adult neurogenesis leading to abnormal cognitive and behavioral performance\(^16,^41\). Importantly, we have previously shown that histamine promotes neurogenesis in the SVZ-olfactory bulb axis of adult healthy mice\(^2\). Moreover, chronic treatment of mice with H3R antagonist resulted in adult hippocampal neurogenesis potentiation and a decrease of cognitive deficits\(^42\), indicating that histamine can be used as a potential therapeutic molecule against neurological disorders. Herein, we unveiled the effects of histamine in adult hippocampal neurogenesis in physiological conditions and under systemic inflammation induced by LPS. In physiological conditions histamine per se slightly improved SGZ cell proliferation (BrdU\(^+\) cells). Nevertheless,
Histamine was able to inhibit LPS-induced decrease on markers correlated with neuronal functionality and synaptic plasticity. Additionally, histamine was able to increase, at long-term, the survival of newborn cells in the DG niche of adult mice, indicating a reversion of LPS-induced hippocampal neuroinflammation by reducing not only the expression levels of markers for activated glial cells but also by decreasing the production of pro-inflammatory molecules. Furthermore, histamine led to reversion of neuroinflammation, neurogenesis impairments and cognitive deficits. These results indicate that histamine is able to revert LPS-induced deficits in the mouse DG, suggesting a possible contribution of histamine in terms of cognition improvement in a neuroinflammatory context, as well as a possible application of this molecule in the treatment of neurological disorders, such as AD, PD and stroke. Therefore, future studies should be done to unveil possible behavior and electrophysiological changes associated to histamine treatment after LPS peripheral administration. Moreover, it would be very interesting to assess more timepoints for histamine administration in order to establish a therapeutic interval where histamine could be used as a therapy against generalized infections.

**Conclusion**

Histamine has been suggested as an important modulator of several CNS functions. Cumulative data have demonstrated a dual role of histamine under different environmental contexts (physiological vs pathological), probably due to the triggering of different receptors and signaling pathways. Histamine *per se* induces a microglial pro-inflammatory phenotype, while it has protective effects under an inflammatory challenge mimicked by LPS counteracting microglial responses. To the best of our knowledge, this is the first study showing the dual effect of histamine on neuroinflammation and neurogenesis in the mouse hippocampus in vivo. Herein, we demonstrated that histamine is able to revert LPS-induced hippocampal neuroinflammation by reducing not only the expression levels of markers for activated glial cells but also by decreasing the production of pro-inflammatory molecules. Additionally, histamine was able to increase, at long-term, the survival of newborn cells in the DG niche of LPS-challenged mice as well as to counteract the SGZ neuroblast loss of volume and dendritic arbor complexity. Histamine was able to inhibit LPS-induced decrease on markers correlated with neuronal functionality and synaptic strength, indicating a reversion of LPS-induced cognitive decline. Interestingly, the protective actions of histamine were stronger when a higher concentration of LPS was used, possibly indicating a dose-dependent effect of LPS in the CNS inflammatory response. This could be a result of differential immune memory triggered by the two LPS dosages used (training vs tolerance) that consequently might have promoted a different response to the secondary inflammatory stimulus (histamine).
Strategies involving attenuation or blockage of the brain inflammatory response in conjugation with the amelioration of neurogenesis impairments might represent a valid therapeutic strategy for several neurodegenerative pathologies. Therefore, our results highlight the potential of histamine as a promising therapeutic agent for conditions that involve neuroinflammation and cognitive deficits.

Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References
1. Barata-Antunes, S., Cristóvão, A. C., Pires, J., Rocha, S. M. & Bernardino, L. Dual role of histamine on microglia-induced neurodegeneration. Biochim. Biophys. Acta 1863, 764–769 (2017).
2. Eiriz, M. F., Valero, J., Malva, J. O. & Bernardino, L. New insights into the role of histamine in subventricular zone-olfactory bulb neurogenesis. Front. Neurosci. 8, 1–7 (2014).
3. Bernardino, L. et al. Histamine stimulates neurogenesis in the rodent subventricular zone. Stem Cells 30, 773–84 (2012).
4. Brown, R. E., Stevens, D. R. & Haas, H. I. The physiology of brain histamine. Prog. Neurobiol. 63, 637–672 (2001).
5. Ferreira, R. et al. Histamine modulates microglia function. J. Neuroinflammation 9, 90 (2012).
6. Dong, H. et al. Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia. Mol. Neurobiol. 49, 1487–500 (2014).
7. Rocha, S. M. et al. Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation. J. Neuroinflammation 13, 137 (2016).
8. Rocha, S. M., Pires, J., Esteves, M., Graça, B. & Bernardino, L. Histamine: a new immunomodulatory player in the neuron-glia crosstalk. Front. Cell. Neurosci. 8, 120 (2014).
9. Dong, H. et al. Histamine H3 receptor in primary mouse microglia inhibits chemotaxis, phagocytosis, and cytokine secretion. Glia 63, 1213–1225 (2015).
10. Wendelin, A.-C. et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature 556, 332–338 (2018).
11. Wasselewska, J. M. et al. Mast cells increase adult neural precursor proliferation and differentiation but this potential is not realized in vivo under physiological conditions. Sci. Rep. 7, 17859 (2017).
12. Rodríguez-Martínez, G. et al. Histamine is required during neural stem cell proliferation to increase neuron differentiation. Neuroscience 216, 10–7 (2012).
13. Molina-Hernández, A. & Velasco, I. Histamine induces neural stem cell proliferation and neuronal differentiation by activation of distinct histamine receptors. J. Neurochem. 106, 706–717 (2008).
14. Takeda, H. et al. Improvement of spatial learning and reduced adult hippocampal neurogenesis in histamine H1-receptor knockout mice. Eur. Neuropsychopharmacol. 24, 1394–404 (2014).
15. Guilloux, J.-P. et al. S 38093, a histamine H3 antagonist/inverse agonist, promotes hippocampal neurogenesis and improves contextual discrimination task in aged mice. Sci. Rep. 7, 42946 (2017).
16. Valero, J., Mastrella, G., Neiva, I., Sánchez, S. & Malva, J. O. Long-term effects of an acute and systemic administration of LPS on adult neurogenesis and spatial memory. Front. Neurosci. 8, 83 (2014).
17. Cazareth, J., Guyon, A., Heurtéaux, C., Chabry, J. & Petit-Pail, A. Molecular and cellular neuroinflammatory status of mouse brain after systemic lipopolysaccharide challenge: importance of CCR2/CCL2 signaling. J. Neuroinflammation 11, 132 (2014).
18. Woywodzic, J. M. & Kee, N. BrdU assay for neurogenesis in rodents. Nat. Protoc. 1, 1399–1405 (2006).
19. Petreanu, L. & Alvarez-Buylla, A. Maturation and death of adult-born olfactory bulb granule neurons: role of olfaction. J. Neurosci. 22, 6106–13 (2002).
20. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–82 (2012).
21. Alberini, C. M. Transcription Factors in Long-Term Memory and Synaptic Plasticity. Physiol. Rev. 89, 121–145 (2009).
22. Saura, C. A. & Valero, J. The role of CREB signaling in Alzheimer’s disease and other cognitive disorders. Rev. Neurosci. 22, 153–69 (2011).
23. Sousa, C. et al. Single-cell transcription reveals distinct inflammation-induced microglia signatures. EMBO Rep. e46171, https:// doi.org/10.15252/embr.201846171 (2018).
24. Qin, L. et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55, 453–62 (2007).
25. Terrano, N. et al. Resolving postoperative neuroinflammation and cognitive decline. Ann. Neurol. 70, 986–995 (2011).
26. Sedeyn, J. C. et al. Histamine Induces Alzheimer’s Disease-Like Blood Brain Barrier Breach and Local Cellular Responses in Mouse Brain Organotypic Cultures. Biomed Res. Int. 2015, 937148 (2015).
27. Stick, L., Rapanelli, M., Abbas, E., Ohtsu, H. & Pittenger, C. Histamine regulation of microglia: Gene-environment interaction in the regulation of central nervous system inflammation. Brain. Behav. Immun. 57, 326–337 (2016).
28. Ulmer, A. J., Rietschel, E. T., Zähringer, U. & Heine, H. Lipopolysaccharide: Structure, Bioactivity, Receptors, and Signal Transduction. Trends Glycosci. Glycotechnol. 14, 53–68 (2002).
29. Raveendran, V. V. et al. Lipopolysaccharide induces H1 receptor expression and enhances histamine responsiveness in human coronary artery endothelial cells. Immunology 132, 578–88 (2010).
30. Shan, Y. et al. H4 Receptor Inhibits Lipopolysaccharide-induced NF-κB Activation by Interacting with Tumor Necrosis Factor Receptor-Associated Factor 6. Neuroscience 398, 113–125 (2019).
31. Furube, E., Kawai, S., Inagaki, H., Takagi, S. & Miyata, S. Brain Region-dependent Heterogeneity and Dose-dependent Difference in Transient Microglia Population Increase during Lipopolysaccharide-induced Inflammation. Sci. Rep. 8, 2003 (2018).
32. Naik, S. et al. Inflammatory memory sensitizes skin epithelial stem cells to tissue damage. Nature 550, 473–480 (2017).
33. Morichuká, T. et al. Histamine inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in an intercellular adhesion molecule-1 and B7.1-dependent manner. J. Pharmacol. Exp. Ther. 310, 617–564–33 (2003).
34. Takahashi, H. K. et al. Histamine downregulates CD14 expression via H2 receptorstimon human monocytes. Clin. Immunol. 108, 274–281 (2003).
35. Alemdac, C. et al. Histamine Regulates Actin Cytoskeleton in Human Toll-like Receptor 4-activated Monocyte-derived Dendritic Cells Tuning CD4+ T Lymphocyte Response. J. Biol. Chem. 291, 14803–14 (2016).
36. Masaki, T. et al. The role of histamine H1 receptor and H2 receptor in LPS-induced liver injury. FASEB J. 19, 1245–52 (2005).
37. Yokoyama, M. et al. Inducible histamine protects mice from P. acnes-primed and LPS-induced hepatitis through H2-receptor stimulation. Gastroenterology 127, 892–902 (2004).
38. Iida, T. et al. Histamine H3 receptor inverse agonist, regulates in vivo microglial functions and improves depression-like behaviours in mice. Biochem. Biophys. Res. Commun. 488, 534–540 (2017).
39. Hu, W. & Chen, Z. The roles of histamine and its receptor ligands in central nervous system disorders: An update. Pharmcol. Ther. 175, 116–132 (2017).
41. Liu, L. et al. Resveratrol counteracts lipopolysaccharide-induced depressive-like behaviors via enhanced hippocampal neurogenesis. Oncotarget 7, 56045–56059 (2016).
42. Bastos, G. N., Moriya, T., Inui, F., Katura, T. & Nakahata, N. Involvement of cyclooxygenase-2 in lipopolysaccharide-induced impairment of the newborn cell survival in the adult mouse dentate gyrus. Neuroscience 155, 454–62 (2008).
43. Mandyam, C. D., Harburg, G. C. & Eisch, A. J. Determination of key aspects of precursor cell proliferation, cell cycle length and kinetics in the adult mouse subgranular zone. Neuroscience 146, 108–22 (2007).
44. Bachstetter, A. D. et al. Spirulina promotes stem cell genesis and protects against LPS induced declines in neural stem cell proliferation. PLoS One 5, e10496 (2010).
45. Monje, M. L., Toda, H. & Palmer, T. D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760–5 (2003).
46. Ormerod, B. K. et al. PPARγ activation prevents impairments in spatial memory and neurogenesis following transient illness. Brain. Behav. Immun. 29, 28–38 (2013).
47. Yu, X.-W., Oh, M. M. & Disterhoft, J. F. CREB, cellular excitability, and cognition: Implications for aging. Behav. Brain Res. 322, 206–211 (2017).
48. Elias, G. M. et al. Synapse-specific and developmentally regulated targeting of AMPA receptors by a family of MAGUK scaffolding proteins. Neuron 52, 307–20 (2006).
49. Ge, L. et al. Resveratrol abrogates lipopolysaccharide-induced depressive-like behavior, neuroinflammatory response, and CREB/BDNF signaling in mice. Eur. J. Pharmacol. 768, 49–57 (2015).
50. Pugazhenthi, S., Wang, M., Pham, S., Sze, C.-I. & Eckman, C. B. Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons. Mol. Neurodegener. 6, 60 (2011).
51. Bartolotti, N., Bennett, D. A. & Lazarov, O. Reduced pCREB in Alzheimer's disease prefrontal cortex is reflected in peripheral blood mononuclear cells. Mol. Psychiatry 21, 1138–66 (2016).
52. Head, E. et al. Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol. Aging 30, 1125–34 (2009).
53. Whitfield, D. R. et al. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. Neurobiol. Aging 35, 2836–2844 (2014).

Acknowledgements
This work was partially supported by “Programa Operacional do Centro, Centro 2020” through the funding of the ICON project (Interdisciplinary Challenges On Neurodegeneration; CENTRO-01-0145-FEDER-000013). This work was also supported by Fundação para a Ciência e a Tecnologia (FCT) and by FEDER funds through the POCI - COMPETE 2020 - Operational Programme Competitiveness and Internationalisation in Axis I - Strengthening research, technological development and innovation (Project POCI-01-0145-FEDER-007491) and National Funds by FCT - Foundation for Science and Technology (Project UID/Multi/00709/2013).

Author Contributions
L.B. designed the study. C.S., S.B.A. performed the experiments and generated and analyzed data. T.S., E.F., A.C.C., C.S.A., R.F. gave technical and scientific support to the realization of the experiments and the respective data analysis. C.S. and L.B. wrote the manuscript. C.S. and S.B.A. prepared the figures. A.C.C., R.F. and L.B. provided resources needed to the realization of the work. L.B. supervised the work. All authors reviewed and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-44816-w.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.